Cytek Biosciences Inc (CTKB)
Return on assets (ROA)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -12,148 | -13,933 | -5,851 | -2,165 | 2,484 | -2,399 | -2,605 | 767 | |||
| Total assets | US$ in thousands | 494,457 | 519,430 | 525,054 | 524,575 | 519,476 | 499,295 | 492,817 | 485,879 | 463,305 | 454,320 | 230,279 |
| ROA | -2.46% | -2.68% | -1.11% | -0.41% | 0.48% | -0.48% | -0.53% | 0.16% |
December 31, 2023 calculation
ROA = Net income (ttm) ÷ Total assets
= $-12,148K ÷ $494,457K
= -2.46%
The return on assets (ROA) for Cytek Biosciences Inc has been fluctuating over the past few quarters. The negative ROA figures in the recent quarters indicate that the company is not efficiently generating profits from its assets. Specifically, the ROA was at its lowest in the Sep 30, 2023 quarter at -2.68%, which suggests that the company's asset utilization and profitability were particularly poor during that period.
It is important for Cytek Biosciences Inc to closely monitor and improve its ROA as it is a key indicator of how well the company is utilizing its assets to generate earnings. The management may need to assess its asset management strategies, efficiency in operations, and overall financial performance to enhance its ROA in the future.
Peer comparison
Dec 31, 2023